Table S1. HCV infecting genotype and antiviral therapies for HIV and HCV in study patients.

Patient (#)	HCV genotype	HCV therapy	HIV antiretroviral therapy
1	3	SOF + DCV	2 NRTI + II
2	1b	SOF + SMV	2 NRTI + II
3	1a	SOF + DCV	2 NRTI + II
4	4	SOF + LDV	
5	1a	SOF + DCV	PI + NNRTI + II
6	1b	SOF + LDV	PI + II + MVC
7	4	SOF + LDV	NRTI + PI
8	1b	SOF + LDV	NNRTI + II
9	1b	SOF + LDV	2 NRTI + II
10	1a	3 DAAs (unspecified)	2 NRTI + II
11	4	SOF + DCV	
12	1a	SOF + SMV	2 NRTI + II
13	1a	SOF + SMV	2 NRTI + II
14	1a	SOF + DCV	2 NRTI + PI
15	1a	SOF + DCV	2 NRTI + II
16	1a	SOF + SMV	2 NRTI + II
17	4	SOF + LDV	2 NRTI + II
18	4	SOF + LDV	2 NRTI + NNRTI
19	1a	SOF + LDV	2 NRTI + II
20	1a	SOF + SMV	2 NRTI + II
21	1a	SOF + LDV	NNRTI + II
22	1a	SOF + LDV	2 NRTI + NNRTI
23	4	SOF + LDV	2 NRTI + II
24	1a	SOF + DCV + SMV	
25	3	SOF + DCV	2 NRTI + PI
26	1a	SOF + LDV	2 NRTI + NNRTI
27	1b	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
28	1a	PEG-IFNα + RBV + PI	
29	1a	PEG-IFNα + RBV + PI	
30	1a	PEG-IFNα + RBV + PI	2 NRTI + PI
31	1a	PEG-IFNα + RBV + PI	2 NRTI + PI
32	1b	PEG-IFNα + RBV + PI	2 NRTI + PI
33	1b	PEG-IFNα + RBV + PI	2 NRTI + PI
34	1a	PEG-IFNα + RBV + PI	2 NRTI + II

35	1b	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
36	3	PEG-IFNα + RBV	2 NRTI + PI
37	3	PEG-IFNα + RBV	2 NRTI + NNRTI
38	1a	PEG-IFNα + RBV + PI	2 NRTI + II
39	1b	PEG-IFNα + RBV + PI	2 NRTI + II
40	MG	PEG-IFNα + RBV + PI	2NRTI + PI
41	1a	PEG-IFNα + RBV + PI	2 NRTI + II
42	1a	PEG-IFNα + RBV	2 NRTI + NNRTI
43	1a	PEG-IFNα + RBV + PI	2 NRTI + II
44	3	PEG-IFNα + RBV	2 NRTI + PI
45	1a	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
46	1b	PEG-IFNα + RBV + PI	II + PI
47	IG	PEG-IFNα + RBV + PI	NRTI + PI
48	1b	PEG-IFNα + RBV + PI	2 NRTI + PI
49	1a	PEG-IFNα + RBV	2 NRTI + II
50	IG	PEG-IFNα + RBV + PI	2 NRTI + II
51	3	PEG-IFNα + RBV + SOF	
52	IG	PEG-IFNα + RBV + SOF	
53	IG	PEG-IFNα + RBV + PI	2 NRTI + II
54	3	PEG-IFNα + RBV	2 NRTI + NNRTI
55	3	PEG-IFNα + RBV + SOF	2 NRTI + NNRTI
56	IG	PEG-IFNα + RBV + PI	2 NRTI + II
57	1a	PEG-IFNα + RBV + PI	2 NRTI + II
58	1a	PEG-IFNα + RBV + PI	2 NRTI + II
59	1a	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
60	1b	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
61	1a	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
62	1b	PEG-IFNα + RBV + PI	2 NRTI + PI
63	1a	PEG-IFNα + RBV	2 NRTI + II
64	1b	PEG-IFNα + RBV + PI	2 NRTI + II
65	1b	PEG-IFNα + RBV + PI	2 NRTI + II
66	MG	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
67	1b	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
68	3	PEG-IFNα + RBV	2 NRTI + NNRTI
69	4	PEG-IFNα + RBV + PI	2 NRTI + PI
70	1a	PEG-IFNα + RBV + PI	2 NRTI + II

71	1b	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
72	1a	PEG-IFNα + RBV + PI	2 NRTI + PI
73	1b	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
74	1a	PEG-IFNα + RBV + PI	2 NRTI + NNRTI
75	3	PEG-IFNα + RBV	NRTI + NNRTI + II
76	1a	PEG-IFNα + RBV + PI	2 NRTI + II

Abbreviations: Patients #**1-26** are HIV/HCV-coinfected individuals who underwent treatment with IFN-free DAA therapy. Patients #**27-76** are HIV/HCV-coinfected individuals who received IFNα-based therapy. DAA = direct-acting antiviral; DCV = daclatasvir; HCV = hepatitis C virus; HIV = human immunodeficiency virus; IFNα = interferon alpha; IG = indeterminate HCV genotypes; II = integrase inhibitor; LDV = ledipasvir; MG = mixed HCV genotypes; MVC = maraviroc; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; Peg-IFNα = pegylated IFNα; PI = protease inhibitor; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir.

Table S2. Comparison of anti-E2 antibody titers (anti-E2-Abs) and neutralizing antibody titers against HCV (anti-HCV-nAbs) between baseline, one-year post-HCV therapy, and five-year post-HCV therapy.

.	**Baseline *vs.* 1-year post-HCV therapy**			**Baseline *vs.* 5-year post-HCV therapy**		
	AMR (95%CI)	***p*-value**	***q*-value**	**AMR (95%CI)**	***p*-value**	***q*-value**
	Anti-E2-Abs					
Gt1a	2.3 (3.3; 1.6)	**<0.001**	**<0.001**	9.1 (13.2; 6.2)	**<0.001**	**<0.001**
Gt1b	2.1 (2.7; 1.6)	**<0.001**	**<0.001**	5 (6.5; 3.8)	**<0.001**	**<0.001**
Gt2a	2.1 (2.6; 1.7)	**<0.001**	**<0.001**	3.6 (4.5; 2.9)	**<0.001**	**<0.001**
Gt3a	1.9 (2.3; 1.6)	**<0.001**	**<0.001**	3.4 (4.1; 2.8)	**<0.001**	**<0.001**
Gt4a	1.9 (2.3; 1.6)	**<0.001**	**<0.001**	3.7 (4.4; 3.1)	**<0.001**	**<0.001**
	Anti-HCV-nAbs					
Gt1a	2.9 (5.7; 1.5)	**0.002**	**0.002**	90.4 (204.5; 40)	**<0.001**	**<0.001**
Gt1b	3 (6; 1.5)	**0.002**	**0.002**	84.5 (185.1; 38.6)	**<0.001**	**<0.001**
Gt2a	3.7 (7.1; 1.9)	**<0.001**	**<0.001**	17.8 (37.3; 8.5)	**<0.001**	**<0.001**
Gt3a	8.4 (20.9; 3.3)	**<0.001**	**<0.001**	34.9 (99.5; 12.3)	**<0.001**	**<0.001**
Gt4a	3 (5.5; 1.6)	**0.001**	**0.001**	49.5 (97.8; 25.1)	**<0.001**	**<0.001**

Statistics: Data were calculated using GLMM. *P*-values were adjusted by the FDR (*q*-value). Significant differences are shown in bold. **Abbreviations**: 95%CI = 95% confidence interval; AMR = arithmetic mean ratio; FDR = false discovery rate; GLMM = generalized linear mixed model; Gt = HCV genotype; HCV = hepatitis C virus.

Table S3. Comparison of neutralizing antibody titers (anti-HCV-nAbs) against Gt3 in relation to those of other chimeric HCV viruses during the follow-up period.

	AMR (95%CI)	*p*-value	*q*-value
Baseline			
Gt1a	8.8 (4.4; 17.6)	**<0.001**	**<0.001**
Gt1b	9.1 (4.5; 18.6)	**<0.001**	**<0.001**
Gt2a	4.8 (2.4; 9.6)	**<0.001**	**<0.001**
Gt3a	Ref.		
Gt4a	5.5 (2.7; 11.2)	**<0.001**	**<0.001**
1-year post-HCV therapy			
Gt1a	9.7 (4.3; 22.2)	**<0.001**	**<0.001**
Gt1b	8.4 (3.7; 19)	**<0.001**	**<0.001**
Gt2a	4.5 (2; 10.1)	**<0.001**	**<0.001**
Gt3a	Ref.		
Gt4a	5.2 (2.3; 11.9)	**<0.001**	**<0.001**
5-year post-HCV therapy			
Gt1a	2.8 (1; 7.8)	**0.051**	**0.051**
Gt1b	3.4 (1.3; 9.2)	**0.014**	**0.019**
Gt2a	12.9 (4.7; 35.5)	**<0.001**	**<0.001**
Gt3a	Ref.		
Gt4a	4 (1.5; 10.6)	**0.005**	**0.010**

Statistics: Data were calculated using GLMM. *P*-values were adjusted by the FDR (*q*-value). Significant differences are shown in bold. **Abbreviations**: 95%CI = 95% confidence interval; AMR = arithmetic mean ratio (Gt/Gt3); FDR = false discovery rate; GLMM = generalized linear mixed model; Gt = HCV genotype; HCV = hepatitis C virus.

Table S4. Comparison of the nonresponse rates of neutralizing antibodies against HCV (anti-HCV-nAbs) between baseline, one-year post-HCV therapy, and five-year post-HCV therapy.

	Baseline *vs.* 1-year post-HCV therapy			**Baseline *vs.* 5-year post-HCV therapy**		
	OR (95%CI)	***p*-value**	***q*-value**	**OR (95%CI)**	***p*-value**	***q*-value**
Gt1a	2.7 (0.7; 10.1)	0.147	0.147	13.5 (4.2; 43.6)	**<0.001**	**<0.001**
Gt1b	3.8 (1.2; 11.3)	**0.019**	0.095	8.2 (2.9; 23)	**<0.001**	**<0.001**
Gt2a	3.3 (0.9; 12.1)	0.067	0.112	6.6 (2; 22.2)	**0.002**	**0.003**
Gt3a	1.6 (1; 2.5)	0.052	0.112	1.8 (1.1; 2.8)	**0.011**	**0.011**
Gt4a	3.5 (0.7; 16.9)	0.118	0.147	12.8 (3; 54.1)	**0.001**	**0.002**

Statistics: Data were calculated using GLMM. *P*-values were adjusted by the FDR (*q*-value). Significant differences are shown in bold. **Abbreviations**: 95%CI = 95% confidence interval; OR = odds ratio; FDR = false discovery rate; GLMM = generalized linear mixed model; Gt = HCV genotype; HCV = hepatitis C virus.

Table S5. Comparison of the nonresponse rates of neutralizing antibodies (anti-HCV-nAbs) against Gt3 in relation to those of other chimeric HCV viruses during the follow-up period.

	OR (95%CI)	*p*-value	*q*-value
Baseline			
Gt1a	9.7 (31.7; 2.9)	**<0.001**	**<0.001**
Gt1b	7.3 (20.6; 2.5)	**<0.001**	**<0.001**
Gt2a	9.4 (30.7; 2.8)	**<0.001**	**<0.001**
Gt3a	Ref.		
Gt4a	14.5 (60.8; 3.5)	**<0.001**	**<0.001**
1-year post-HCV therapy			
Gt1a	5.8 (12.2; 2.7)	**<0.001**	**<0.001**
Gt1b	3.1 (5.5; 1.7)	**<0.001**	**<0.001**
Gt2a	4.6 (9.1; 2.3)	**<0.001**	**<0.001**
Gt3a	Ref.		
Gt4a	6.6 (14.6; 3)	**<0.001**	**<0.001**
5-year post-HCV therapy			
Gt1a	1.3 (1.9; 0.9)	**0.217**	**0.217**
Gt1b	1.6 (2.5; 1)	**0.033**	**0.044**
Gt2a	2.6 (4.4; 1.6)	**<0.001**	**<0.001**
Gt3a	Ref.		
Gt4a	2 (3.3; 1.3)	**0.003**	**0.006**

Statistics: Data were calculated using GLMM. *P*-values were adjusted by the FDR (*q*-value). Significant differences are shown in bold. **Abbreviations**: 95%CI = 95% confidence interval; OR = odds ratio; FDR = false discovery rate; GLMM = generalized linear mixed model; Gt = HCV genotype; HCV = hepatitis C virus.